問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2394Cases

2022-04-15 - 2023-10-11

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-12-31 - 2025-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-01-01 - 2031-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2024-12-01 - 2027-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-12-01 - 2023-10-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2016-03-07 - 2020-02-26

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-10-01 - 2024-12-31

Others

A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer.

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    MTL-CEBPA

Participate Sites
4Sites

Terminated3Sites

Suspended1Sites

2017-06-08 - 2019-04-30

Phase II

An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects with Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    SCB01A

Participate Sites
4Sites

Terminated4Sites

張牧新
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏和雄
Taipei Medical University Hospital

Division of Hematology & Oncology

2017-01-01 - 2028-12-31

Phase II

A Phase II, Dose-randomization, Open-label Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    PTS100

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2018-03-01 - 2020-02-29

Phase II

A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects with Hair Loss

  • Condition/Disease

    Hair Loss

  • Test Drug

    ENERGI-F701

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

陳志強
Taipei Veterans General Hospital

Division of Dermatology

1 198 199 200 201 202 240
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB